Takaaki Chou

Niigata Kenshin Plaza
Niigata, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma.

Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma.

Journal: Annals of hematology

Published: July 11, 2023

Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma.

Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma.

Journal: Annals of hematology

Published: December 13, 2022

Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma.

Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma.

Journal: Future oncology (London, England)

Published: July 11, 2022

Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance.

Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance.

Journal: Internal medicine (Tokyo, Japan)

Published: October 14, 2021

A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.

A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.

Journal: International journal of clinical oncology

Published: June 02, 2021

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies.

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies.

Journal: Leukemia & lymphoma

Published: October 28, 2020

Retraction Note to: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey.

Retraction Note to: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey.

Journal: International journal of hematology

Published: October 08, 2020

Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies.

Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies.

Journal: Cancer science

Published: July 27, 2020

The 31-nucleotide Y4-RNA fragment in plasma is a potential novel biomarker.

The 31-nucleotide Y4-RNA fragment in plasma is a potential novel biomarker.

Journal: Non-coding RNA research

Published: November 21, 2019

Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.

Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.

Journal: Leukemia & lymphoma

Published: August 23, 2019

Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan.

Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan.

Journal: International journal of hematology

Published: August 05, 2019

High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey.

High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey.

Journal: International journal of hematology

Published: July 09, 2019

Showing 1-12 of 48

Last Updated: 09/26/2026